These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
176 related items for PubMed ID: 11069195
1. Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis. Crilly RG, Sebaldt RJ, Hodsman AB, Adachi JD, Brown JP, Goldsmith CH, Hanley DA, Olszynski WO, Ste-Marie LG, Stephenson GF. Osteoporos Int; 2000; 11(7):607-14. PubMed ID: 11069195 [Abstract] [Full Text] [Related]
2. Response to alendronate in osteoporosis after previous treatment with etidronate. Fairney A, Kyd P, Thomas E, Wilson J. Osteoporos Int; 2000; 11(7):621-5. PubMed ID: 11069197 [Abstract] [Full Text] [Related]
3. [The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis]. Nakamura T, Maekawa S, Morinobu S, Morinobu A, Koshiba M, Yamauchi M, Sugimoto T, Kumagai S. Ryumachi; 2002 Aug; 42(4):666-75. PubMed ID: 12355861 [Abstract] [Full Text] [Related]
4. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis. Iwamoto J, Takeda T, Ichimura S, Matsu K, Uzawa M. J Orthop Sci; 2003 Aug; 8(4):532-7. PubMed ID: 12898306 [Abstract] [Full Text] [Related]
5. Effects of combined treatment with etidronate, nandrolone-decanoate and calcium on bone mineral density in postmenopausal women. Bolanca S, Korsić M, Dekanić D, Cvijetić S. Acta Med Croatica; 1998 Aug; 52(3):159-63. PubMed ID: 9818438 [Abstract] [Full Text] [Related]
6. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H, Risedronate Phase III Research Group. Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940 [Abstract] [Full Text] [Related]
7. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Diamond T, McGuigan L, Barbagallo S, Bryant C. Am J Med; 1995 May; 98(5):459-63. PubMed ID: 7733124 [Abstract] [Full Text] [Related]
8. Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures. Anderson FH, Francis RM, Bishop JC, Rawlings DJ. Age Ageing; 1997 Sep; 26(5):359-65. PubMed ID: 9351480 [Abstract] [Full Text] [Related]
9. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup. Sato S, Ohosone Y, Suwa A, Yasuoka H, Nojima T, Fujii T, Kuwana M, Nakamura K, Mimori T, Hirakata M. J Rheumatol; 2003 Dec; 30(12):2673-9. PubMed ID: 14719212 [Abstract] [Full Text] [Related]
10. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. Adachi J, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividino A, Craig GL, Kaminska E, Sebaldt RJ, Papaioannou A. J Rheumatol; 1994 Oct; 21(10):1922-6. PubMed ID: 7837160 [Abstract] [Full Text] [Related]
11. Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study. Popp AW, Guler S, Lamy O, Senn C, Buffat H, Perrelet R, Hans D, Lippuner K. J Bone Miner Res; 2013 Mar; 28(3):449-54. PubMed ID: 23018784 [Abstract] [Full Text] [Related]
12. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Struys A, Snelder AA, Mulder H. Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482 [Abstract] [Full Text] [Related]
13. 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis. Sebaldt RJ, Ioannidis G, Adachi JD, Bensen WG, Bianchi F, Cividino A, Gordon M, Kaminska E, Scocchia T, Petrie A, Stephenson GF, Goldsmith CH. J Rheumatol; 1999 Jul; 26(7):1545-9. PubMed ID: 10405943 [Abstract] [Full Text] [Related]
14. Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup. Sato S, Takada T, Katsuki Y, Kimura N, Kaneko Y, Suwa A, Hirakata M, Kuwana M. J Rheumatol; 2008 Jan; 35(1):142-6. PubMed ID: 18050368 [Abstract] [Full Text] [Related]
18. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD. Osteoporos Int; 2000 Jul 12; 11(5):434-42. PubMed ID: 10912846 [Abstract] [Full Text] [Related]
19. Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy. Kitatani K, Nakatsuka K, Naka H, Miki T, Morii H, Nishizawa Y. J Bone Miner Metab; 2003 Jul 12; 21(4):217-24. PubMed ID: 12811626 [Abstract] [Full Text] [Related]